Off-label indications for atypical antipsychotics: A systematic review

Annals of General Hospital Psychiatry

Volumn 3, Issue , 2004, Pages

  Fountoulakis, Konstantinos N ^a   Nimatoudis, Ioannis ^a   Iacovides, Apostolos ^a   Kaprinis, George ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Atypical antipsychotics; Depression; OCD; Off label prescription; Personality disorders; Pervasive developmental disorder; Pharmacotherapy; Stuttering; Tourette's syndrome

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; FLUOXETINE; HALOPERIDOL; NORADRENALIN; OLANZAPINE; PIMOZIDE; QUETIAPINE; RISPERIDONE;

BIPOLAR DISORDER; BODY WEIGHT DISORDER; BORDERLINE STATE; CLINICAL TRIAL; DEMENTIA; DEPRESSION; DEVELOPMENTAL DISORDER; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE RESPONSE; DRUG DEPENDENCE; DRUG MECHANISM; DRUG TOLERABILITY; FATIGUE; GILLES DE LA TOURETTE SYNDROME; HUMAN; MEDICAL RESEARCH; MEDLINE; MEMORY DISORDER; META ANALYSIS; OBSESSIVE COMPULSIVE DISORDER; POSTTRAUMATIC STRESS DISORDER; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SCORING SYSTEM; SEDATION; SIDE EFFECT; STUTTERING; SUBSTANCE ABUSE; SYSTEMATIC REVIEW; TREATMENT INDICATION;

EID: 3042604516     PISSN: 14752832     EISSN: None     Source Type: Journal    
DOI: 10.1186/1475-2832-3-4     Document Type: Review

References (121)

1. Potenza MN, McDougle CJ: Potential of Atypical Antipsychotics in the Treatment of NonPsychotic Disorders. CNS Drugs 1998, 9:213-232.
2. Schweitzer I: Does Risperidone have a place in the treatment of nonschizophrenic patients? International Clinical Psychopharmacology 2001:1-19.
3. Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. Journal of Clinical Psychiatry 1994, 55 suppl:5-12.
4. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, W Arnot: A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology 1993:25-40.
5. Marder SR, Meilbach RC: Risperidone in the treatment of Schizophrenia. American Journal of Psychiatry 1994, 151:825-835.
6. Kapur S, Seeman P: Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?: A new hypothesis. American Journal of Psychiatry 2001, 158:360-369.
7. Kapur S, Zipursky RB, Remington G: Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone and olanzapine in schizophrenia. American Journal of Psychiatry 1999, 156:286-293.
8. Jadad A, Moore A, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Controlled Clinical Trials 1996, 17:1-12.
9. Ad-Dab'bagh Y, Greenfield B, Milne-Smith J, Freedman H: Inpatient treatment of severe disruptive behaviour disorders with risperidone and milieu therapy. Can J Psychiatry 2000, 45:376-382.
10. Andrade C: Risperidone may worsen fluoxetine-treated OCD. J Clin Psychiatry 1998, 59:255-256.
11. Bourgeois JA, Klein M: Risperidone and fluoxetine in the treatment of pedophilia with comorbid dysthymia. J Clin Psychopharmacol 1996, 16:257-258.
12. Bruggeman R, van der Linden C, Buitelaar JK, Gericke GS, Hawkridge SM, Temlett JA: Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study. J Clin Psychiatry 2001, 62:50-56.
13. Bruun RD, Budman CL: Risperidone as a treatment for Tourette's syndrome. J Clin Psychiatry 1996, 57:29-31.
14. Buitelaar JK: Open-label treatment with risperidone of 26 psychiatrically-hospitalized children and adolescents with mixed diagnoses and aggressive behavior. J Child Adolesc Psychopharmacol 2000, 10:19-26.
15. Buitelaar JK, van der Gaag RJ, Cohen-Kettenis P, Melman CT: A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry 2001, 62:239-248.
16. Dartnall NA, Holmes JP, Morgan SN, McDougle CJ: Brief report: two-year control of behavioral symptoms with risperidone in two profoundly retarded adults with autism. J Autism Dev Disord 1999, 29:87-91.
17. Demb HB: Risperidone in young children with pervasive developmental disorders and other developmental disabilities. J Child Adolesc Psychopharmacol 1996, 6:79-80.
18. Doan RJ: Risperidone for insomnia in PDDs. Can J Psychiatry 1998, 43:1050-1051.
19. Dryden-Edwards RC, Reiss AL: Differential response of psychotic and obsessive symptoms to risperidone in an adolescent. J Child Adolesc Psychopharmacol 1996, 6:139-145.
20. Eidelman I, Seedat S, Stein DJ: Risperidone in the treatment of acute stress disorder in physically traumatized in-patients. Depress Anxiety 2000, 11:187-188.
21. Epperson CN, Fasula D, Wasylink S, Price LH, McDougle CJ: Risperidone addition in serotonin reuptake inhibitor-resistant trichotillomania: three cases. J Child Adolesc Psychopharmacol 1999, 9:43-49.
22. Fisman S, Steele M: Use of risperidone in pervasive developmental disorders: a case series. J Child Adolesc Psychopharmacol 1996, 6:177-190.
23. Fitzgerald KD, Stewart CM, Tawile V, Rosenberg DR: Risperidone augmentation of serotonin reuptake inhibitor treatment of pediatric obsessive compulsive disorder. J Child Adolesc Psychopharmacol 1999, 9:115-123.
24. Gabriel A: A case of resistant trichotillomania treated with risperidone-augmented fluvoxamine. Can J Psychiatry 2001, 46:285-286.
25. Giakas WJ: Risperidone treatment for a Tourette's disorder patient with comorbid obsessive-compulsive disorder. Am J Psychiatry 1995, 152:1097-1098.
26. Grabowski J, Rhoades H, Silverman P, Schmitz JM, Stotts A, Creson D, Bailey R: Risperidone for the treatment of cocaine dependence: randomized, double-blind trial. Journal of Clinical Psychopharmacology 2000, 20:305-310.
27. Hanna GL, Fluent TE, Fischer DJ: Separation anxiety in children and adolescents treated with risperidone. J Child Adolesc Psychopharmacol 1999, 9:277-283.
28. Hardan A, Johnson K, Johnson C, Hrecznyj B: Case study: risperidone treatment of children and adolescents with developmental disorders. J Am Acad Child Adolesc Psychiatry 1996, 35:1551-1556.
29. Hirose S: Effective treatment of aggression and impulsivity in antisocial personality disorder with risperidone. Psychiatry Clin Neurosci 2001, 55:161-162.
30. Horrigan JP, Barnhill LJ: Risperidone and explosive aggressive autism. J Autism Dev Disord 1997, 27:313-323.
31. Jacobsen FM: Risperidone in the treatment of affective illness and obsessive-compulsive disorder. J Clin Psychiatry 1995, 56:423-429.
32. Kawahara T, Ueda Y, Mitsuyama Y: A case report of refractory obsessive-compulsive disorder improved by risperidone augmentation of clomipramine treatment. Psychiatry Clin Neurosci 2000, 54:599-601.
33. Khouzam HR, Donnelly NJ: Remission of self-mutilation in a patient with borderline personality during risperidone therapy. J Nerv Ment Dis 1997, 185:348-349.
34. Knopf U, Hubrich-Ungureanu P, Thome J: [Paroxetine augmentation with risperidone in therapy-resistant depression]. Psychiatr Prax 2001, 28:405-406.
35. Krashin D, Oates EW: Risperidone as an adjunct therapy for post-traumatic stress disorder. Mil Med 1999, 164:605-606.
36. Lombroso PJ, Scahill L, King RA, Lynch KA, Chappell PB, Peterson BS, McDougle CJ, Leckman JF: Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report. J Am Acad Child Adolesc Psychiatry 1995, 34:1147-1152.
37. Maguire GA, Gottschalk LA, Riley GD, Franklin DL, Bechtel RJ, Ashurst J: Stuttering: neuropsychiatric features measured by content analysis of speech and the effect of risperidone on stuttering severity. Compr Psychiatry 1999, 40:308-314.
38. Masi G, Cosenza A, Mucci M, Brovedani P: Open trial of risperidone in 24 young children with pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 2001, 40:1206-1214.
39. Masi G, Cosenza A, Mucci M, De Vito G: Risperidone monotherapy in preschool children with pervasive developmental disorders. J Child Neurol 2001, 16:395-400.
40. McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH: A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000, 57:794-801.
41. McDougle CJ, Fleischmann RL, Epperson CN, Wasylink S, Leckman JF, Price LH: Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases. J Clin Psychiatry 1995, 56:526-528.
42. McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, Price LH: A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry 1998, 55:633-641.
43. Miodownik C, Lerner V: Risperidone in the treatment of psychotic depression. Clin Neuropharmacol 2000, 23:335-337.
44. Monnelly EP, Ciraulo DA: Risperidone effects on irritable aggression in posttraumatic stress disorder. J Clin Psychopharmacol 1999, 19:377-378.
45. Newton TF, Ling W, Kalechstein AD, Uslaner J, Tervo K: Risperidone pre-treatment reduces the euphoric effects of experimentally administered cocaine. Psychiatry Research 2001, 102:227-233.
46. Nicolson R, Awad G, Sloman L: An open trial of risperidone in young autistic children. J Am Acad Child Adolesc Psychiatry 1998, 37:372-376.
47. O'Connor M, Silver H: Adding risperidone to selective serotonin reuptake inhibitor improves chronic depression. J Clin Psychopharmacol 1998, 18:89-91.
48. Ostroff RB, Nelson JC: Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry 1999, 60:256-259.
49. Perry R, Pataki C, Munoz-Silva DM, Armenteros J, Silva RR: Risperidone in children and adolescents with pervasive developmental disorder: pilot trial and follow-up. J Child Adolesc Psychopharmacol 1997, 7:167-179.
50. Pfanner C, Marazziti D, Dell'Osso L, Presta S, Gemignani A, Milanfranchi A, Cassano GB: Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study. Int Clin Psychopharmacol 2000, 15:297-301.
51. Posey DJ, Walsh KH, Wilson GA, McDougle CJ: Risperidone in the treatment of two very young children with autism. J Child Adolesc Psychopharmacol 1999, 9:273-276.
52. Purdon SE, Lit W, Labelle A, Jones BD: Risperidone in the treatment of pervasive developmental disorder. Can J Psychiatry 1994, 39:400-405.
53. Raheja RK, Bharwani I, Penetrante AE: Efficacy of risperidone for behavioral disorders in the elderly: a clinical observation. J Geriatr Psychiatry Neurol 1995, 8:159-161.
54. Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G: Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder (OCD). Psychopharmacol Bull 1996, 32:677-682.
55. Sandor P, Stephens RJ: Risperidone treatment of aggressive behavior in children with Tourette syndrome. J Clin Psychopharmacol 2000, 20:710-712.
56. Saxena S, Wang D, Bystritsky A, Baxter L. R., Jr.: Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry 1996, 57:303-306.
57. Schreier HA: Risperidone for young children with mood disorders and aggressive behavior. J Child Adolesc Psychopharmacol 1998, 8:49-59.
58. Seedat S, Kesler S, Niehaus DJ, Stein DJ: Pathological gambling behaviour: emergence secondary to treatment of Parkinson's disease with dopaminergic agents. Depress Anxiety 2000, 11:185-186.
59. Smelson DA, Roy A, Roy M: Risperidone diminishes cue-elicited craving in withdrawn cocaine-dependent patients. Can J Psychiatry 1997, 42:984.
60. Stein DJ, Bouwer C, Hawkridge S, Emsley RA: Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. J Clin Psychiatry 1997, 58:119-122.
61. Stoll AL, Haura G: Tranylcypromine plus risperidone for treatment-refractory major depression. J Clin Psychopharmacol 2000, 20:495-496.
62. Sun TF, Lin PY, Wu CK: Risperidone augmentation of specific serotonin reuptake inhibitors in the treatment of refractory obsessive-compulsive disorder: report of two cases. Chang Gung Med J 2001, 24:587-592.
63. Van Bellinghen M, De Troch C: Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial. J Child Adolesc Psychopharmacol 2001, 11:5-13.
64. van der Linden C, Bruggeman R, van Woerkom TC: Serotonin-dopamine antagonist and Gilles de la Tourette's syndrome: an open pilot dose-titration study with risperidone. Mov Disord 1994, 9:687-688.
65. Vercellino F, Zanotto E, Ravera G, Veneselli E: Open-label risperidone treatment of 6 children and adolescents with autism. Can J Psychiatry 2001, 46:559-560.
66. Zuddas A, Di Martino A, Muglia P, Cianchetti C: Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation. J Child Adolesc Psychopharmacol 2000, 10:79-90.
67. Findling RL, Maxwell K, Wiznitzer M: An open clinical trial of risperidone monotherapy in young children with autistic disorder. Psychopharmacology Bulletin 1997, 33:155-159.
68. Adli M, Rossius W, Bauer M: [Olanzapine in the treatment of depressive disorders with psychotic symptoms]. Nervenarzt 1999, 70:68-71.
69. Ashton AK: Olanzapine augmentation for trichotillomania. Am J Psychiatry 2001, 158:1929-1930.
70. Benazzi F: Fluoxetine and Olanzapine for Resistant Depression. Am J Psychiatry 2002, 159:155.
71. Bhadrinath BR: Olanzapine in Tourette syndrome. Br J Psychiatry 1998, 172:366.
72. Bogetto F, Bellino S, Vaschetto P, Ziero S: Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial. Psychiatry Res 2000, 96:91-98.
73. Budman CL, Gayer A, Lesser M, Shi Q, Bruun RD: An open-label study of the treatment efficacy of olanzapine for Tourette's disorder. J Clin Psychiatry 2001, 62:290-294.
74. Butterfield MI, Becker ME, Connor KM, Sutherland S, Churchill LE, Davidson JR: Olanzapine in the treatment of post-traumatic stress disorder: a pilot study. Int Clin Psychopharmacol 2001, 16:197-203.
75. Francobandiera G: Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study. Can J Psychiatry 2001, 46:356-358.
76. Garnis-Jones S, Collins S, Rosenthal D: Treatment of self-mutilation with olanzapine. J Cutan Med Surg 2000, 4:161-163.
77. Ghaemi SN, Cherry EL, Katzow JA, Goodwin FK: Does olanzapine have antidepressant properties? A retrospective preliminary study. Bipolar Disord 2000, 2:196-199.
78. Grant JE: Successful treatment of nondelusional body dysmorphic disorder with olanzapine: a case report. J Clin Psychiatry 2001, 62:297-298.
79. Gupta MA, Gupta AK: Olanzapine is effective in the management of some self-induced dermatoses: three case reports. Cutis 2000, 66:143-146.
80. Gupta MA, Gupta AK: Olanzapine may be an effective adjunctive therapy in the management of acne excoriee: a case report. J Cutan Med Surg 2001, 5:25-27.
81. Hansen L: Olanzapine in the treatment of anorexia nervosa. Br J Psychiatry 1999, 175:592.
82. Hough DW: Low-dose olanzapine for self-mutilation behavior in patients with borderline personality disorder. J Clin Psychiatry 2001, 62:296-297.
83. Jensen VS, Mejlhede A: Anorexia nervosa: treatment with olanzapine. Br J Psychiatry 2000, 177:87.
84. Konig F, von Hippel C, Petersdorff T, Neuhoffer-Weiss M, Wolfersdorf M, Kaschka WP: First experiences in combination therapy using olanzapine with SSRIs (citalopram, paroxetine) in delusional depression. Neuropsychobiology 2001, 43:170-174.
85. Koran LM, Ringold AL, Elliott MA: Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2000, 61:514-517.
86. Krishnamoorthy J, King BH: Open-label olanzapine treatment in five preadolescent children. J Child Adolesc Psychopharmacol 1998, 8:107-113.
87. La Via MC, Gray N, Kaye WH: Case reports of olanzapine treatment of anorexia nervosa. Int J Eat Disord 2000, 27:363-366.
88. Labbate LA, Douglas S: Olanzapine for nightmares and sleep disturbance in posttraumatic stress disorder (PTSD). Can J Psychiatry 2000, 45:667-668.
89. Malek-Ahmadi P, Simonds JF: Olanzapine for autistic disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 1998, 37:902.
90. Malone RP, Cater J, Sheikh RM, Choudhury MS, Delaney MA: Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry 2001, 40:887-894.
91. Nelson LA, Swartz CM: Melancholic symptoms during concurrent olanzapine and fluoxetine. Ann Clin Psychiatry 2000, 12:167-170.
92. Onofrj M, Paci C, D'Andreamatteo G, Toma L: Olanzapine in severe Gilles de la Tourette syndrome: a 52-week doubleblind cross-over study vs. low-dose pimozide. J Neurol 2000, 247:443-446.
93. Petty F, Brannan S, Casada J, Davis LL, Gajewski V, Kramer GL, Stone RC, Teten AL, Worchel J, Young KA: Olanzapine treatment for post-traumatic stress disorder: an open-label study. Int Clin Psychopharmacol 2001, 16:331-337.
94. Pitchot W, Ansseau M: Addition of olanzapine for treatment-resistant depression. Am J Psychiatry 2001, 158:1737-1738.
95. Potenza MN, Holmes JP, Kanes SJ, McDougle CJ: Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol 1999, 19:37-44.
96. Potenza MN, Wasylink S, Epperson CN, McDougle CJ: Olanzapine augmentation of fluoxetine in the treatment of trichotillomania. Am J Psychiatry 1998, 155:1299-1300.
97. Rothschild AJ, Bates KS, Boehringer KL, Syed A: Olanzapine response in psychotic depression. J Clin Psychiatry 1999, 60:116-118.
98. Schulz SC, Camlin KL, Berry SA, Jesberger JA: Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biol Psychiatry 1999, 46:1429-1435.
99. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, Buras WR, Bymaster FP, Zhang W, Spencer KA, Feldman PD, Meltzer HY: A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001, 158:131-134.
100. Soler J, Campins MJ, Perez V, Puigdemont D, Perez-Blanco E, Alvarez E: [Olanzapine and cognitive-behavioural group therapy in borderline personality disorder]. Actas Esp Psiquiatr 2001, 29:85-90.
101. Squitieri F, Cannella M, Piorcellini A, Brusa L, Simonelli M, Ruggieri S: Short-term effects of olanzapine in Huntington disease. Neuropsychiatry Neuropsychol Behav Neurol 2001, 14:69-72.
102. Stamenkovic M, Schindler SD, Aschauer HN, De Zwaan M, Willinger U, Resinger E, Kasper S: Effective open-label treatment of tourette's disorder with olanzapine. Int Clin Psychopharmacol 2000, 15:23-28.
103. Weisler RH, Ahearn EP, Davidson JR, Wallace CD: Adjunctive use of olanzapine in mood disorders: five case reports. Ann Clin Psychiatry 1997, 9:259-262.
104. Zanarini MC, Frankenburg FR: Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry 2001, 62:849-854.
105. Khullar A, Chue P, Tibbo P: Quetiapine and obsessive-compulsive symptoms (OCS): case report and review of atypical antipsychotic-induced OCS. J Psychiatry Neurosci 2001, 26:55-59.
106. Martin A, Koenig K, Scahill L, Bregman J: Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 1999, 9:99-107.
107. Padla D: Quetiapine resolves psychotic depression in an adolescent boy. J Child Adolesc Psychopharmacol 2001, 11:207-208.
108. Parraga HC, Parraga MI, Woodward RL, Fenning PA: Quetiapine treatment of children with Tourette's syndrome: report of two cases. J Child Adolesc Psychopharmacol 2001, 11:187-191.
109. APA: Diagnostic and Statistical Manual of Mental Disorder, 4th Edition. Washington DC, American Psychiatric Press; 1994.
110. Shapiro E, Shapiro AK,, Fulop G: Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome. Archives of General Psychiatry 1989, 46:722-730.
111. Caine ED, Polinsky RJ, Kartzinel R: The trial use of clozapine for abnormal involuntary movement disorders. American Journal of Psychiatry 1979:317-320.
112. Anderson LT, Cambell M, Grega DM, Perry R, Small AM, Green WH: Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. American Journal of Psychiatry 1984, 141:1195-1202.
113. Gordon CT, Rapoport JL, Hamburger SD, State RC, Mannheim GB: Differential response of seven subjects with autistic disorder to clomipramine and desipramine. American Journal of Psychiatry 1992, 149:363-366.
114. Gordon CT, State RC, Nelson JE, Hamburger SD, Rapoport JL: A double-blind comparison of clomipramine, desipramine and placebo in the treatment of autistic disorder. Archives of General Psychiatry 1993, 50:441-447.
115. McDougle CJ, Naylor ST, Cohen DJ, FV Volkmar, Heninger GR, LH Price: A double-blind placebo-controlled study of fluvoxamine in adults with autistic disorder. Archives of General Psychiatry 1996, 53:1001-1008.
116. Meert TF, PAJ Janssen: Ritanserin: a new therapeutic approach for drug abuse. Part 2: effects on cocaine. Drug Development Research 1992:39-53.
117. Schotte A, Janssen PMF, Gommeren W, Luyten WHML, VanGompel P, Lesage AS, DeLoore K, Leysen J: Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berlin) 1996:57-73.
118. McDougle CJ, Goodman WK, Price LH, Delgado PL, Krystal JH, Charney DS, Heninger GR: Haloperidol addition in fluvoxamine-refractory obssessive-compulsive disorder: a double-blind placebo-controlled study in patients with and without tics. American Journal of Psychiatry 1990:302-308.
119. Zhang W, Perry WK, Wong DT, Potts BD, Bao J, Tollefson GD, Bymaster FP: Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on neorepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 2000:250-262.
120. Leone NF: Response of borderline patients to loxapine and chlorpromazine. Journal of Clinical Psychiatry 1982:148-150.
121. Soloff PH, George A, Nathan RS: Amitriptyline versus haloperidol in borderlines: final outcome and predictors of response. Journal of Clinical Psychopharmacology 1989:238-246.